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METHODS
Figure 1- Effect of oseltamivir on neuraminidase activity by subtype
The effect of oseltamivir on viral neuraminidase activity was performed
using a commercially available kit (NA-Star®Influenza Neuraminidase
Inhibitor Resistance Detection Kit, Applied Biosystems, Foster City, CA)
in 96-well solid white microplates following the manufacturer’s
instructions. Oseltamivir in half-log dilution increments was incubated
with virus (as the source of neuraminidase). Plates were pre-
incubated for 10 minutes prior to addition of chemiluminescent
substrate. Following addition of substrate plates were incubated for 10
min at 37oC. The neuraminidase activity was evaluated using a Centro
LB 960 luminometer (Berthold Technologies) for 0.5 sec immediately
after addition of NA-Star® accelerator solution.
Viral neuraminidase inhibition assay
Aquatic birds are the natural reservoirs of a wide variety of influenza A
viruses. Novel influenza strains occasionally emerge from wild bird
populations and spread to other species. Historically, pandemic
influenza strains crossing over to humans have led to serious outbreaks.
The rapid evolution of influenza strains in birds presents a major public
health concern. Globalization and intensified agriculture have increased
human contact with avian influenzas in the past century. Antiviral drugs
effective against influenza are an important part of preparing for
outbreaks, as well as common seasonal flu’s. Two major classes of
antiviral drugs widely used against influenza are M2 inhibitors and
neuraminidase inhibitors. The M2 inhibitor amantadine was approved by
the FDA in 1966. More than 30 years later the neuraminidase inhibitor
oseltamivir was approved for use against the flu in 1999, marketed as
Tamiflu®. Unfortunately, flu viruses are highly mutable and can quickly
develop resistance to treatment. Resistance has been observed to both
amantadine and oseltamivir, with resistance to amantadine especially
widespread since its introduction 50 years ago. Monitoring levels of drug
sensitivity in natural flu strains collected from the wild is one way to
understand how different strains are affected by antiviral drugs and how
resistance spreads.
Twenty-one influenza A viruses were obtained from the American Type
Culture Collection (ATCC), from subgroups H1-H9, collected from wild
birds. Stocks of each influenza virus isolate were prepared and
enumerated (titered). Dose of virus needed to kill 50% of individual cell
cultures (CCID50) was determined by endpoint dilution assay.
Drug efficacy of both oseltamivir and amantadine was compared
against 11 isolates by cell culture assay in 96-well plates. Madin-Darby
canine kidney (MDCK) cells were grown in MEM supplemented with 5%
FBS. Virus was prepared in MEM containing Trypsin (10 Units/ml) and
EDTA (1 µg/ml) final concentration. Drug diluted in half-log increments
was added, each dilution was assayed in three replicates. Cells were
incubated with virus and drug dilution and observed for cytopathic
effect on days 3 and 6. Cytopathic effect was then measured by neutral
red assay.
Endpoint dilution antiviral assay
Figure 2- Cell culture EC50 of  amantadine by year isolate was obtained Figure 3- Cell culture EC50 of  oseltamivir by year isolate was obtained
CONCLUSIONS
These studies showed significant differences in oseltamivir sensitivity
between the different N-subtypes in the sample set. The results did not
show significant correlation between the year the isolate was obtained and
the drug sensitivity profile of the strain. Further studies will verify the results
on a larger sample size and examine other factors (region, species, etc.) for
correlation with drug sensitivity.
Figure 4- Cytopathic effect visible on 96-well cell culture assay after 
addition of neutral red stain (day 6)
